tag:blogger.com,1999:blog-3139696084392272622.post8416960622288854943..comments2024-03-29T00:31:51.931+00:00Comments on HyperCRYPTICal: A Nice U-turn by NICE.hyperCRYPTICalhttp://www.blogger.com/profile/11967085628384237933noreply@blogger.comBlogger3125tag:blogger.com,1999:blog-3139696084392272622.post-87349303522942425492010-10-13T22:00:33.406+01:002010-10-13T22:00:33.406+01:00I would take it also, and may need it as my dotage...I would take it also, and may need it as my dotage is fast approaching!Anonymousnoreply@blogger.comtag:blogger.com,1999:blog-3139696084392272622.post-82192370765972428982010-10-08T19:04:23.101+01:002010-10-08T19:04:23.101+01:00Thanks for your comment drphil.
You are of course...Thanks for your comment drphil.<br /><br />You are of course, correct on all counts.<br /><br />However, AchEIs can offer (to some) a temporary reprieve in symptoms, in particular, behaviour, cognition and functional ability.<br /><br />If this reprieve lasts, say for a year, cost effectiveness comes to the fore, especially in respect of unpaid carers.<br /><br />Meds costs per annum of £1,092 v care home costs of a minimum of £26,000? I know which appears the most sensible to me. But, I guess it depends on where the funding is coming from and the NHS doesn't have the luxury of a bottomless money pit.<br /><br />It is a sad thing that Alzheimers - along with most other dementia's - is a progressive disease for which there is no cure. But given the chance of a (temporary) reprieve in symptoms as against nothing at all - I would take it.<br /><br />Amma :o]hyperCRYPTICalhttps://www.blogger.com/profile/11967085628384237933noreply@blogger.comtag:blogger.com,1999:blog-3139696084392272622.post-69525603696338389562010-10-07T23:24:11.903+01:002010-10-07T23:24:11.903+01:00One of the problems with the NICE process, is that...One of the problems with the NICE process, is that they do change their minds if a well organised campaign is organised. Drug companies are fully aware of this, and help finance the campaigns. Pfizer gave £28000 to the Alzheimers society last year.<br /><br />So cost efficacy decisions are over ridden if there are enough Daily Mail headlines. I am not sure that this is wise, it sets up the next campaign for a NICE rejected drug.<br /><br />In a condition as demoralising as Alzheimers there is a strong desire for effective drugs, but desire is not efficacy.Anonymousnoreply@blogger.com